NCT00788684 2025-02-20Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersAbbViePhase 1 Completed29 enrolled
NCT00406809 2021-08-02A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesAbbViePhase 1/2 Completed81 enrolled